At what stage is this treatment used?
- Adjuvant treatment of stage III (Dukes C) colon cancer after complete resection of primary tumour.
- Treatment of metastatic bowel cancer.
Is Eloxatin available on the Pharmaceutical Benefits Scheme (PBS) as a subsidised treatment?
- Eloxatin in combination with 5-FU and folinic acid (FOLFOX) is PBS-subsidised as a treatment option for the adjuvant treatment of patients with stage III (Dukes C) colon cancer following complete resection of the primary tumour.
- Eloxatin in combination with 5-FU and folinic acid (FOLFOX) or Xeloda (XELOX) is PBS-subsidised as a treatment option for patients with metastatic bowel cancer.
- Eloxatin is not PBS-subsidised for the treatment of patients with stage II (Dukes B) colon cancer. Eloxatin is not PBS-subsidised for the adjuvant treatment of patients with rectal cancer.
- Xeloda (capecitabine) in combination with Eloxatin (XELOX) is listed as a PBS-subsidised treatment option for the adjuvant treatment of stage III (Dukes C) colon cancer, which allows Xeloda to be reimbursed as both monotherapy and as part of the XELOX combination.
Download the Consumer Medicine Information (CMI) for Eloxatin.
